Design and synthesis of leucylaniline derivatives as leucyl-tRNA synthetase inhibitors
作者:Jinghan Luo、Chengjun Wu、Yanjun Hu、Xingxing Jia、Yu Chen、Tiemin Sun
DOI:10.1039/d1nj04543a
日期:——
By simulating the structure of Leu-AMP, an intermediate of tRNA synthesis, 26 leu-arylamine derivatives were designed and synthesized by retaining leucine and replacing adenosine phosphate with amido-substituted aniline. All compounds were designed under the guidance of computer aided drug design, and their drug-like properties were fully considered. The inhibitory activities of all compounds against
通过模拟tRNA合成中间体Leu-AMP的结构,设计合成了26个leu-arylamine衍生物,保留亮氨酸,用氨基取代的苯胺代替磷酸腺苷。所有化合物均在计算机辅助药物设计指导下进行设计,并充分考虑了其类药性质。测试了所有化合物对 LeuRS 抑制酶和草分枝杆菌 1180的抑制活性。大多数化合物显示出对 LeuRS 抑制酶和草分枝杆菌 1180的抑制活性。六种化合物(18、19、20、21、24和25 _ _ _ _ _ _) 使用结核分枝杆菌 H37Ra进行筛选。这些化合物对结核分枝杆菌H37Ra有很强的抑制作用。分子对接研究也显示出同样的结果,充分验证了设计思路。我们还发现化合物上氢键受体的存在导致与蛋白质的关键氨基酸形成强氢键。
Synthesis and Evaluation of <i>N</i>-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV)
Small molecule induced hepatitisBvirus (HBV) capsidassembly modulation is considered an attractive approach for new antiviral therapies against HBV. Here we describe efforts toward the discovery of a HBV capsidassemblymodulator in a hit-to-lead optimization, resulting in JNJ-632, a tool compound used to further profile the mode of action. Administration of JNJ-632 (54) in HBV genotype D infected